Patents by Inventor Michael Rivard

Michael Rivard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200114235
    Abstract: The present application describes a bag throwing game board and game. Players take a plurality of soft bags that are approximately round in shape and throw them from a distance towards the game board, which in various examples is in the shape of a tower, and has holes. Points are attributed to bags landing in different holes of the board, depending on the difficulty of landing the bag in each hole. After a series of throws, the point scores are totaled and the player earning the most points or the player first to reach a score goal wins.
    Type: Application
    Filed: July 23, 2019
    Publication date: April 16, 2020
    Inventor: Michael Rivard
  • Patent number: 10519179
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 31, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Roberto Motterlini, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • Patent number: 10125157
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 13, 2018
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmaele, Joachim Caron
  • Patent number: 10098901
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic uses thereof, in particular for treating or preventing cancer.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: October 16, 2018
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Didier Desmaele, Charles Skarbek, Patrick Couvreur
  • Publication number: 20180258121
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Application
    Filed: September 23, 2016
    Publication date: September 13, 2018
    Inventors: Roberto MOTTERLINI, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • Publication number: 20180207503
    Abstract: The present application describes a bag throwing game board and game. Players take a plurality of soft bags that are approximately round in shape and throw them from a distance towards the game board, which in various examples is in the shape of a tower, and has holes. Points are attributed to bags landing in different holes of the board, depending on the difficulty of landing the bag in each hole. After a series of throws, the point scores are totaled and the player earning the most points or the player first to reach a score goal wins.
    Type: Application
    Filed: December 15, 2017
    Publication date: July 26, 2018
    Inventor: Michael Rivard
  • Patent number: 9944669
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 17, 2018
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto Motterlini, Roberta Foresti, Thierry Martens, Michael Rivard
  • Publication number: 20170360964
    Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogues, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.
    Type: Application
    Filed: August 3, 2017
    Publication date: December 21, 2017
    Inventors: THIERRY MARTENS, MICHAEL RIVARD, CELINE LAURENCE, CHRISTOPHE MORIN, SONIA LEHRI-BOUFALA, NARIMANE ZEGHBIB
  • Patent number: 9744250
    Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogs, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: August 29, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
    Inventors: Thierry Martens, Michaël Rivard, Céline Laurencé, Christophe Morin, Sonia Lehri-Boufala, Narimane Zeghbib
  • Publication number: 20170174716
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto MOTTERLINI, Roberta FORESTI, Thierry MARTENS, Michael RIVARD
  • Publication number: 20170071959
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines, pharmaceutical compositions and therapeutic use thereof, in particular for treating or preventing cancer.
    Type: Application
    Filed: May 13, 2015
    Publication date: March 16, 2017
    Inventors: ANGELO PACI, THIERRY MARTENS, MICHAEL RIVARD, DIDIER DESMAELE, CHARLES SKARBEK, PATRICK COUVREUR
  • Publication number: 20160333038
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Application
    Filed: July 28, 2016
    Publication date: November 17, 2016
    Inventors: ANGELO PACI, THIERRY MARTENS, MICHAEL RIVARD, PATRICK COUVREUR, DIDIER DESMAELE, JOACHIM CARON
  • Patent number: 9428530
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: August 30, 2016
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmaele, Joachim Caron
  • Publication number: 20150328338
    Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogues, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.
    Type: Application
    Filed: November 19, 2013
    Publication date: November 19, 2015
    Inventors: THIERRY MARTENS, MICHAËL RIVARD, CÉLINE LAURENCÉ, CHRISTOPHE MORIN, SONIA LEHRI-BOUFALA, NARIMANE ZEGHBIB
  • Publication number: 20150315220
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Application
    Filed: July 2, 2015
    Publication date: November 5, 2015
    Inventors: ANGELO PACI, THIERRY MARTENS, MICHAEL RIVARD, PATRICK COUVREUR, DIDIER DESMAELE, JOACHIM CARON
  • Patent number: 9073957
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: July 7, 2015
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmael, Joachim Caron
  • Publication number: 20130261088
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Application
    Filed: December 9, 2011
    Publication date: October 3, 2013
    Applicant: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmael, Joachim Caron
  • Patent number: 8119403
    Abstract: The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: February 21, 2012
    Assignee: Sanofi Pasteur Vaxdesign Corp.
    Inventors: William L. Warren, Russell Higbee, Eric Mishkin, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Michael Rivard
  • Patent number: D722527
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: February 17, 2015
    Inventors: Lisa Rivard, Michael Rivard
  • Patent number: D898122
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: October 6, 2020
    Assignee: Rivard Companies, Inc.
    Inventor: Michael Rivard